Activating SCN1A to Treat Dravet Syndrome
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.
Selecting CAR T-Cell Therapies for Mantle Cell Lymphoma: Jae Park, MD
The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.
Patient Considerations in R/R Mantle Cell Lymphoma Treatment: Anita Kumar, MD
The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.
Brexucabtagne Autoleucel's Efficacy in ALL: Bijal Shah, MD, MS
The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.
Novel Treatments for Multiple Myeloma: C. Ola Landgren, MD, PhD
The inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.
Improving AAV Production With HeLa Platform
Sam Wadsworth, PhD, chief scientific officer of Ultragenyx Pharmaceuticals, discussed the company’s platform for efficiently producing AAV vectors.
Targeting Relapsing/Refractory Multiple Myeloma With Cell Therapy
The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma.
Investigating JSP191 for More Tolerable Gene and Cell Therapy Conditioning
The executive vice president of research and development at Jasper Therapeutics discussed positive data from trials of JSP191 in MDS and AML.
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder Cancer
The chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
CAR T-Cell Therapy for Mantle Cell Lymphoma: Tycel Jovelle Phillips, MD
The clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.
Targeting Leptomeningeal Brain Tumors With CAR T Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
The Need for New Therapies in DLBC Lymphoma: Gilles Salles, MD
The lymphoma service chief at Memorial Sloan Kettering Cancer Center discussed the need for new therapies to treat diffuse large B-cell lymphoma.
CAR T and Other Approaches for Patients with R/R DLBC Lymphoma
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Improving Gene and Cell Therapy Conditioning Regimens With JSP191
The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.
Novel Treatments for Hematologic Malignancies: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer
The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.
Benefits of CAR T Therapy in Follicular Lymphoma: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
Advantages of Manufacturing Cell Therapies In-House
The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
DLBCL Second-Line Therapy Recommendations
Experts discussed their recommendations for second-line treatment options for patients with DLBCL.
Unique Challenges With Gene Therapy in Duchenne Muscular Dystrophy
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed challenges in developing gene therapies for DMD.
Exploring Advanced Approaches for Pain Relief
The chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
Novel Therapies in Development for Dravet Syndrome
Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.
Improving Efficiency in CAR T Cell Therapy Production
The chief technology officer of Mustang Bio discussed the company’s approach and future plans in CAR T production.
Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
CD20-Targeted Gene Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MD
The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Challenges in Conducting Research in DMD
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed some challenges the company is facing.
Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD
The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.
Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
Future Research With Car T-Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.
